Article

UC Davis receives AMD grant

University of California, Davis researchers have received a 3-year, $1.8 million grant from the National Eye Institute to study the cellular changes that cause age-related macular degeneration.

Sacramento, CA-University of California, Davis (UC Davis) researchers have received a 3-year, $1.8 million grant from the National Eye Institute (NEI) to study the cellular changes that cause age-related macular degeneration (AMD).

With this funding, UC Davis researchers will look at how the retinal pigment epithelium (RPE) is affected by epigenetic factors-changes that alter gene expression while leaving the original genome sequence intact. Preliminary research by the team showed that the expression in several genes important to RPE cells changes with age.

“We want to know the biochemical changes in retinal cells that occur with aging and increase the susceptibility for this disease,” said Larry Hjelmeland, PhD, principal investigator on the grant and professor of ophthalmology with the UC Davis Eye Center.

“Looking at aging as an epigenetic phenomenon clearly represents a big step forward for the study of AMD,” added Dr. Hjelmeland, whose project is one of the first to be funded by the NEI to explore the link between epigenetics and eye disease.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.